

ISSN : 2321-9602



Indo-American Journal of Agricultural and Veterinary Sciences



editor@iajavs.com
iajavs.editor@gmail.com



Methods for the Anti-inflammatory Synthesis, Molecular Modeling, and Biological Evaluation of Novel Pyrimidine Derivatives

Ms. M. Jyothi¹, Mr. K. Naga Surendra², Ms. A. Padmavathi³, Mr. K. Mahendranath⁴,
Ms. K. Sai Sireesha⁵, Dr. C.H. Rajaharanadha babu⁶

ABSTRACT

The 2-thioxo-1,2,3,4- tetrahydropyrimidine derivative 1 was synthesized using direct Biginelli condensation, and it was then employed in the synthesis of a novel series of pyrimidin-2-thione derivatives (2a-d to 7a-b) with the goal of generating new anti-inflammatory medicines.

Using the carrageenan-induced rat paw edema test, we compared the anti-inflammatory effects of each chemical to those of ibuprofen, the gold standard in this field. SYBLYL-X v.2.1 was used for the molecular docking analyses.

Docking tests demonstrate strong agreement with anti-inflammatory findings, and a sequence of pyrimidine derivatives made using a simple and readily accessible approach leads to a molecule with promise anti-inflammatory action. To confirm the significance of these novel compounds for diverse applications, more study is needed. Location and Timing of Education: Faculty of Pharmacy, Helwan University, Cairo, Egypt, Department of Pharmaceutical Organic Chemistry and Department of Pharmacology and Toxicology, February 2018 – March 2019.

The compounds had anti-inflammatory effectiveness ranging from 61% to 86%, with ibuprofen performing at 69%. At 4 hours post-carrageenan, compounds 2a, 2b, 2c, 2d, 3a, 3b, 3c, 3d, 7a, 7b exhibited substantially different levels of anti-inflammatory action compared to ibuprofen.

Keywords: Anti-inflammatory; biginelli; cyclooxygenase inhibition; molecular docking; pyrimidine; SAR.

1. INTRODUCTION

The pyrimidine ring represents one of the most important medicinal chemistry scaffolds. The biological activities of pyrimidine derivatives are multiple and include antibacterial, antimicrobial [1-3], antitubercular [4-6], anticancer [7], anti-HIV [8,9], antioxidant [10,11], anti-leishmanial [12], antiviral [13], anti-diabetic [14-16], antithyroid [17,18], anticonvulsant [19] and anti-Alzheimer activities [20]. Pyrimidine ring [21] is also an integral

part of DNA nucleic acid composition which explains the fact that pyrimidine derivatives display diverse medicinal activities. Acetamine **I**, Afloqualone **II**, Proquazone **III** exhibited good NSAID potential, and Epirazole **IV**, another NSAID, is reported as a COX-2 inhibitor, are examples for drugs containing pyrimidine moiety that was synthesized and used as Analgesics and NSAID [22] [Fig. 1].

Department of Pharmaceutical Analysis^{1,2,3,4,5,6}

Approved by AICTE & Pharmacy Council of India, New Delhi. (Affiliated to Jawaharlal Nehru Technological University, Anantapur & S.B.T.E.T.A.P)

Chennai-Hyderabad By Pass Road, Ukkayapalli, Kadapa-516002




Fig. 1. Anti-inflammatory drugs (NSAIDs)




Fig. 2. Some reported pyrimidine containing anti-inflammatory agents

Non-steroidal anti-inflammatory drugs (NSAIDs) are among the most successful and widely prescribed drugs known to alleviate pain, fever and inflammation [34]. Their anti-inflammatory efficacy has been attributed to their inhibition of cyclooxygenase (COX) enzymes (COX-1 and COX-2), which lead to suppression of prostaglandin H₂ (PGH₂) biosynthesis from arachidonic acid (AA) [35]. Present NSAIDs drugs inhibit both COX-1 and COX-2 with minimal specificity [36] and possess serious side effects, mainly gastric ulcers, cardiovascular and renal toxicities [37]. Therefore, the development of new compounds having anti-inflammatory activity with an improved selectivity against the COX-2 enzyme and safety profile is still a necessity.

Motivated by these facts, herein we report the synthesis, *in vivo* anti-inflammatory activity of novel pyrimidin-2-thione derivatives by the carrageenan-induced rat paw edema assay. Moreover, the most active compounds were evaluated for their *in vitro* COX-1/COX-2 inhibition. Structure and activity relationship (SAR) and molecular modeling study were also investigated.

2. MATERIALS AND METHODS

2.1 Chemistry

All melting points were determined in capillary tube on a Boetius melting point microscope and were uncorrected. FT-IR spectra were recorded as KBr pellets on a Perkin-Elmer 1650 spectrophotometer (USA), Faculty of Science, Cairo University, Cairo, Egypt. ¹H NMR and ¹³C- NMR spectra (Supplementary data) were recorded in DMSO-d₆ on a Varian Mercury (300 MHz) spectrometer (Varian UK) and chemical shifts were given as ppm from TMS as internal

reference (Faculty of Science, Cairo University, Cairo, Egypt). Mass spectra were recorded on 70 eV EI Ms-QP 1000 EX (Shimadzu, Japan), Faculty of Science, Cairo University, and Cairo, Egypt. Microanalyses were performed using Vario, Elementar apparatus (Shimadzu, Japan), Organic Microanalysis Unit, Faculty of Science, Cairo University, Cairo, Egypt and the results were within the accepted range (0.40) of the calculated values.

2.2 Methods

1- {4-[4-(Dimethylamino)phenyl]-6-methyl-2-thioxo-1,2,3,4-tetrahydropyrimidin-5-yl} ethanone (1)

The titled compound was synthesized by direct Biginelli condensation method [38].

General procedure for preparation

ne), 2.50 (s,6H, 2CH₃), 5.00 (s,1H, pyrimidine), 7.19-8.65 (m,9H,Ar-H),10.04, 10.64 (s,2H,2NH, D₂O exchangeable). ¹³C NMR (300 MHz, DMSO-d₆): 178.7(C=S) ,164.8 (C=N) , 99.8(C, C-5) ,146.4 (C, C-6) ,128.0 (CH₃),118.6, 125.9, 126.8 ,127.1,128.5, 130.0, 140.0, 150.7 (Ar/olefinic carbon), 55.8 (C, C-4),40.6 (NCH₃) ,18.3 (CH₃). Anal. Calcd. for C₂₁H₂₄N₄S(364.507): C, 69.20 ; H, 6.64 ; N, 15.37; S, 8.80%. Found: C, 69.21; H, 6.66;N, 15.39; S,8.87%.

4-(4-Dimethylamino-phenyl)-6-methyl-5-(1-o-tolylimino-ethyl)-3,4-dihydro-1H-pyrimidine-2-thione (2b)

Yield: 86%. m.p. 168-170°C. IR (KBr) ν (cm⁻¹): 3385 (NH), 1600 (C=N), 1220 (C=S). MS (EI) m/z: 378(M+,30%). ¹H NMR(DMSO-d₆,300MHz) δ (ppm):2.01(s,3H,CH₃),2.25(s,3H,CH₃, pyrimidine) ,2.3(s,3H,CH₃),2.5(s,6H,CH₃),5.00(s,1H, pyrimidine), 6.68-7.55 (m, 8H,Ar-H),9.60, 9.70 (s,2H, 2NH, D₂O exchangeable) . ¹³C NMR (300 MHz, DMSO-d₆):178.3(C=S) ,164.2(C=N) , 99.5(C, C-5) ,145 (C, C-6) ,128 (CH₃) ,149.7,142.3,132, 131,130,128.5,126.9,126.8,121.9,112.5 Ar/ olefinic carbon), 54(C, C-4),40(NCH₃) ,12,18.5 (CH₃). Anal. Calcd. for C₂₂H₂₆ N₄S (378.533): C,69.80; H,6.92; N,14.80; S, 8.47%. Found: C, 69.89; H,6.98; N,14.87; S,8.49%.

4-(4-Dimethylamino-phenyl)-6-methyl-5-(1-(4-acetophenylimino)ethyl)-3,4-dihydro-1H-pyrimidine-2-thione (2c)

Yield: 83%. m.p. 140-142°C. IR(KBr) ν (cm-1): 3380 (NH), 1590 (C=N), 1690(C=O), 1215(C=S). MS (EI)m/z:406.(M+,35%). ¹H NMR(DMSO-d₆, 300MHz) δ (ppm): 2.20(s,3H,CH₃),2.26(s,3H, CH₃ , pyrimidine), 2.40 (s,3H, CH₃,COCH₃), 2.5 (s,

of compound (2)

The appropriate primary amine was added to a solution of the pyrimidine derivative **1** (0.01 mol) in absolute ethanol (50 ml) containing 1% conc. H₂SO₄. The reaction mixture was heated under reflux for 3-5 h; the resulted product was cooled, poured onto ice-water (100 ml) and neutralized with 25% ammonia solution (0.5 ml). The produced precipitate was filtered and recrystallized from ethanol to give compounds **2a-d**.

4-(4-Dimethylamino-phenyl)-6-methyl-5-(1-phenylimino-ethyl)-3,4-dihydro-1H-pyrimidine-2-thione (2a)

Yield: 80%. m.p. 155-160°C. IR (KBr) ν (cm⁻¹): 3382 (NH), 1584 (C=N), 1245 (C=S). MS (EI) m/z: 364(M+,20%). ¹H NMR(DMSO-d₆, 300 MHz) δ (ppm):2.23(s,3H,CH₃),2.34(s,3H,CH₃, pyrimidi-

6H, CH₃), 5.16(s,1H, pyrimidine),6.60-7.76(m, 8H,Ar-H), 9.60, 9.78 (s,2H,2NH, D₂O exchange- eable). ¹³C NMR (300 MHz,DMSO-d₆):196 (C=O) ,179 (C=S) ,165(C=N) , 98(C, C-5), 146 (C, C-6) ,128.5 (CH₃), 112,121,121.9,128.2, 129, 131, 142.2, 135, 153 (Ar/ olefinic carbon),52(C, C-4) , 40.3(NCH₃) ,22.8 (CH₃), 18.5 (CH₃). Anal. Calcd.C₂₃H₂₆N₄OS (406. 543): C,7.95 ;H, 6.45;N, 13.78; S,7.89%. Found: C,7.97; H,6.43 ;N,13.70; S,7.80%.

5-[1-(3-Chloro-phenylimino)-ethyl]-4-(4-dimethylamino-phenyl)-6-methyl-3,4-dihydro-1H-pyrimidine-2-thione (2d)

Yield: 80%. m.p.170-175°C. IR (KBr) ν (cm⁻¹): 3390 (NH), 1600 (C=N), 1210 (C=S). MS (EI) m/z: 398 (M+, 3.8 %), 400 (M+2, 1.2 %). ¹H NMR (DMSO-d₆, 300 MHz) δ (ppm): 2.08 (s,3H,CH₃), 2.25 (s, 3H, CH₃, pyrimidine), 2.5 (s,6H, CH₃),5.2 (s, 1H, pyrimidine), 6.90-7.45 (m,8H,Ar-H), 9.98,10.2 (s,2H,2NH, D₂O exchangeable). ¹³C NMR (300 MHz, DMSO-d₆): 178(C=S) , 162(C=N) , 97(C, C-5) ,144(C, C-6) ,128 (CH₃) ,112.2,120,122, 127,128, 131, 131.5, 135,142.5 ,150(Ar/olefinic carbon), 53(C, C-4) , 43.3(NCH₃),18.1(CH₃). Anal.Calcd.for C₂₁H₂₃Cl N₄S (398.952): C,63.22; H,5.81;N,14.04; S, 8.04%. Found: C, 63. 20; H,5.83; N,14.09; S, 8.08%.

General procedure for preparation of compound 3

To a hot solution of paraformaldehyde (0.9 g, 0.01 mol) and the appropriate amine (0.01 mol) in absolute ethanol (25 ml), methyl ketone **1** in 10 ml ethanol was added. The reaction mixture was heated for 3-6 h, Then it was cooled, and the precipitate was filtered off, dried, and crystallized from methanol to

afford compounds **3a-d**.

1-[4-(4-Dimethylamino-phenyl)-6-methyl-2-thioxo-1,2,3,4-tetrahydropyrimidine-5-yl]-3-phenyl amino-propan-1-one (3a)

Yield:79%. m.p. 250-252°C. IR(KBr)v(cm⁻¹):3345 (NH),2986(CH-aliphatic),3167(CH-aromatic), 684 (C=O). MS (E1) m/z: 394(M⁺, 64%). ¹H NMR (DMSO-d₆, 300MHz) δ (ppm):2.24 (s,3H, CH₃, pyrimidine), 2.50 (s,6H,2CH₃),3.40 (t,2H,CH₂), 3.73 (t,2H,CH₂), 5.15 (s,1H, Pyrimidine),5.90 (s, 1H,NH,D₂O exchangeable), 7.16-8.89(m,9H, Ar-H),10.84,11.64(s,2H,NH,pyrimidine D₂O exchangeable). ¹³C NMR (300 MHz, DMSO-d₆): 197.0 (C=O), 178.0(C=S), 103.0(C, C-5), 150.0(C, C-6), 111.0, 112.1, 116.0,128.2,129.0, 131.1, 142.2 ,143.0(Ar/olefinic carbon),55.0(C, C-4), 43.0

MHz,DMSO-d₆): 197.1(C=O), 179.5(C=S), 103.3 (C,C-5),150.7(C, C-6), 113.3,116.4,118.6, 126.8, 128.7 ,128. 9,130.0, 142.9,145.9 (Ar/olefinic carbon) , 55.8(C, C-4), 42.4 (NCH₃) , 40.2, 45.6 (2CH₂), 21.3 (CH₃), 13.3(CH₃) .Anal. Calcd for C₂₃H₂₈ N₄OS:(408.56): C,67.61;H, 6.91;N, 13.71;S, 7.85%. Found: C, 67.59;H, 6.79;N, 13.67;S, 7.90%.

3-(4-Acetylphenylamino)-1-[4-(4-dimethyl amino-phenyl)-6-methyl-2-thioxo-1,2,3,4-tetrahydro pyrimidine-5-yl]-propan-1-one (3c).

Yield:73%. m.p. 225-227°C. IR (KBr)v (cm⁻¹): 3366 (NH),2981(CH-aliphatic), 3179 (CH- aromatic), 1688 (C=O). MS (E1)m/z: 436(M⁺, 52%). ¹H NMR (DMSO-d₆,300MHz) δ(ppm): 2.25(s,3H, CH₃, pyrimidine), 2.40(s,3H,CH₃, CH₃CO), 2.5 (s,6H, 2CH₃),3.2 (t,2H, CH₂), 3.3(t,2H, CH₂), 5.2(s,1H, pyrimidine), 5.8(s,1H, NH,D₂O exchan- geable), 7.1-7.8 (m,8H, Ar-H),9.6,9.7 (2H,NH, pyrimidine D₂O exchangeable) . ¹³C NMR (300 MHz, DMSO-d₆): 196.5,197.1 (2C=O), 178.2 (C=S), 103.2(C, C-5),150.2(C, C-6) ,112.0, 112.4 ,125.0, 128.4, 129.0, 131.4, 142.4,147.0 (Ar/ olefinic carbon),55.0(C, C-4), 43.0(NCH₃), 40.1, 45.0 (2CH₂),22.8, 21.0(2CH₃). Anal. Calcd for C₂₄H₂₈N₄O₂S (436. 57): C,66. 03;H,6.46; N,12. 83; S,7.34%. Found: C,66.19;H, 6.39;N, 12.87;S, 7.45%.

3-(3-Chloro-phenylimino)-1-[4-(4-dimethyl amino-phenyl)-6-methyl-2-thioxo-1,2,3,4-tetrahydro pyrimidine-5-yl]-propan-1-one (3d).

Yield:86%.m.p.265-267°C. IR (KBr) v(cm⁻¹): 3360 (NH), 2977 (CH-aliphatic), 3198 (CH-aromatic) ,1689(C=O). MS(E1)m/z:428(M⁺,67%),430 (M+2, 20.1%). ¹HNMR (DMSO-d₆,300MHz) δ(ppm), 2.26 (s,3H,CH₃,pyrimidine) ,2.5 (s, 6H, 2CH₃),3.1 (t,2H, CH₂), 3.2 (t,2H,CH₂), 5.3 (s,1H, pyrimidine) ,5.8 (1H,NH, D₂O exchangeable) ,7.3-7.8 (m,

(NCH₃), 40.0, 45.0 (2CH₂), 21.0 (CH₃). Anal. Calcd for C₂₂H₂₆N₄OS (394.533): C, 66.97;H, 6.64;N,14.20;S, 8.13%. Found: C, 66.95; H, 6.70;N,14.17;S, 8.03%.

1-[4-(4-Dimethylamino-phenyl)-6-methyl-2- thioxo-1,2,3,4-tetrahydropyrimidine-5-yl]-3-o- tolyl amino -propan-1-one (3b).

Yield:81%. m.p. 245-47°C. IR(KBr)v(cm⁻¹):3344 (NH), 2959 (CH-aliphatic), 3124(CH-aromatic), 1685(C=O). MS (E1) m/z: 408(M⁺, 65%). ¹H NMR(DMSO-d₆, 300MHz) δ (ppm): 2.49 (s,3H, CH₃, pyrimidine), 2.63 (s,6H, 2CH₃),2.83 (s,3H, CH₃),3.03 (t,2H, CH₂), 3.34 (t,2H,CH₂), 5.23(s, 1H,pyrimidine), 5.90(1H, NH, D₂Oexchangeable) ,6.44-8.09(m,8H,Ar-H),9.04,10.09(s,2H,NH, pyr - imidine D₂O exchangeable). ¹³C NMR (300

10% ethanolic sodium hydroxide solution (60 ml) was stirred at room temperature for 24 h. The mixture was then heated for 1-3 h, cooled, poured into ice-water and acidified with conc. HCl. The precipitate was filtered off, dried and recrystallized from aqueous DMF to give compounds **4a-d**.

1-[4-(4-Dimethylaminophenyl)-6-methyl-2-thioxo-1,2,3,4-tetrahydropyrimidin-5-yl]-3-phenyl-prop-2-en-1-one (4a)

Yield: 87%. m.p. 210-212°C. IR(KBr)v(cm⁻¹):3442 (NH),2943(CH-aliphatic),3077(CH-aromatic). 685 (C=O). MS (E1) m/z: 377(M⁺,67%). ¹HNMR (DMSO-d₆,300MHz)δ (ppm):2.25(s,3H, CH₃, pyrimidine),2.5(s,6H, 2CH₃)5.1 (s,1H, pyrimidine) ,7.07,7.11 (dd,2CH, CH=CH),7.13-7.55(m,9H, Ar-H), 9.50, 9.88 (s, 2H , NH, pyrimidine D₂O exchangeable). ¹³C NMR (300 MHz, DMSO-d₆): 187.3(C=O) , 178.4(C=S) , 159.6(C, C-6) ,129.6, 136.6(2CH),118.6(C,C-5),113.9, 126.9, 127.3, 128.6, 126.2, 128.1, 130.0, 145.3 (Ar/olefinic carbon),53.3 (C, C-4), 43.2(NCH₃), 18.6(CH₃). Anal. Calcd for C₂₂H₂₃N₃OS(377.50): C,70.00;H, 6.14; N, 11.13 ; S, 8.49%.Found:C,70.17; H,6.24; N,11.17; S, 8.50%.

1-[4-(4-Dimethylaminophenyl)-6-methyl-2- thioxo-1,2,3,4-tetrahydropyrimidin-5-yl]-3-(4- methoxy phenyl)- prop-2-en-1-one (4b)

Yield: 83%.m.p. 217-219°C. IR (KBr) v (cm⁻¹): 3387 (NH), 2978 (CH-aliphatic), 3191 (CH-aromatic). 1675 (C=O). MS (E1)m/z: 407 (M⁺,77%). ¹HNMR (DMSO-d₆, 300MHz)δ(ppm): 2.25(s,3H, CH , pyrimidine), 2.55(s,6H,2CH) ,

8H,Ar-H),9.6, 9.8(s,2H, NH, pyrimidine D₂O exchangeable). ¹³C NMR (300 MHz, DMSO-

3.8(s,3H,OCH₃),5.1(s,1H,pyrimidine),6.2,6.4(dd,2CH,CH=CH),7.17-8.395 (m,8H, Ar-H), 10.0, 11.0 (s, 2H, NH, pyrimidine D₂O exchangeable). ¹³C NMR (300 MHz, DMSO-d₆): 187(C=O), 178 d6):197.2(C=O),178.2(C=S),103.5(C, C-5),150.5 (C,C-6),110.0, 112.0, 112.6, 117.0, 128.5,130.0,131.5,134.0,142.6,144.0(Ar/olefinic carbon), 55.0 (C, C-4), 43.0 (NCH₃), 40.5, 45.2 (2CH₂), 21.5 (CH₃). Anal. Calcd for C₂₂H₂₅ClN₄OS (428.98) : C, 61.60;H, 5.87;N,13.06;S, 7.47%. Found C, 61.59;H, 5.79;N,13.10;S, 7.50%.

General procedure for preparation of compound 4

A mixture of methyl ketone **1** (0.01 mole) and the appropriate aromatic aldehyde (0.01 mole) in

NMR (DMSO-d₆, 300MHz) δ(ppm):2.28 (s,3H, CH₃, pyrimidine),2.5(s,6H, 2CH₃),4.2 (s,9H, 3OCH₃), 5.1(s,1H, Pyrimidine), 6.4,6.5 (dd,2CH, CH=CH),7.3-7.9(m,6H,Ar-H),9.7,10.1 (s,2H,NH, pyrimidine D₂O exchangeable). ¹³C NMR (300 MHz, DMSO-d₆): 187.2(C=O), 178.2(C=S), 159(C, C-6),129.2,134.2 (2CH), 116(C, C-5),105, 112.4, 129, 129.2, 131.4, 132,142.2, 148(Ar/olefinic carbon), 56.3,56.6 (OCH₃),53.2 (C, C-4), 43.2(NCH₃), 18(CH₃). Anal. Calcd for C₂₅H₂₉N₃O₄S (467.58): C, 64.22;H, 6.25;N,8.99; S, 6.86%. Found :C, 64.31;H, 6.28; N,8.87;S, 6.79%.

3-(4-Dimethylamino phenyl)-1-[4-(4-dimethyl amino phenyl)-6-methyl-2-thioxo-1,2,3,4-tetra hydro pyrimidin-5-yl]-prop-2-en-1-one (4d)

Yield: 79%. m.p. 230-232°C. IR(KBr)v(cm⁻¹): 3388 (NH),2973 (CH-aliphatic), 3167 (CH-aromatic), 1679 (C=O). MS(E1)m/z: 420(M⁺,77%). ¹H NMR (DMSO-d₆,300MHz)δ (ppm): 2.25 (s,3H, CH₃, pyrimidine), 2.35,2.6 (s,12H, 4CH₃), 5.2(s,1H, Pyrimidine), 6.3,6.4 (dd,2CH, CH=CH),7.2-7.9(m,8H, Ar-H),9.7,9.9 (s, 2H, NH, pyrimidine D₂O exchangeable). ¹³C NMR (300 MHz, DMSO-d₆):187.5(C=O), 178.5 (C=S), 159.5(C, C-6),129,134(2CH), 116.5(C, C-5),112.5, 113,124,127, 129.1,131.5,142.1, 143(Ar/ olefinic carbon),53(C, C-4), 43(NCH₃), 18(CH₃). Anal. Calcd for C₂₄H₂₈N₄OS (420.57): C, 68.54;H, 6.71; N, 13.32;S, 7.62%. Found: C, 68.87; H, 6.66;N,13.29;S, 7.61%.

General procedure for preparation of compound 5

A mixture of methyl ketone **1** (0.003 mole), the appropriate aromatic aldehyde(0.003 mole), ammonium acetate (1.89 g,8 mole) and ethyl cyanoacetate (0.003 mole) in 60 ml absolute ethanol was refluxed for about 5-8 h. The reaction mixture was concentrated to its half volume, cooled, filtered off and the filtrate was poured into ice/ water and the

(C=S), 159.2(C, C-6),129,134(2CH), 116.2 (C, C-5),114,112.2, 120,127,128, 129.2, 131.2, 142.2, 159(Ar/olefinic carbon),56(OCH₃),53.2(C, C-4), 43.2(NCH₃), 18(CH₃). Anal. Calcd for C₂₅H₂₅N₃O₂S (407.53):C, 67.79;H, 6.18; N, 10.31;S, 7.87%. Found: C, 67.87;H, 6.20; N,10.27; S, 7.71%.

1-[4-[4-(Dimethyl amino phenyl)-6-methyl-2-thioxo-1,2,3,4-tetrahydropyrimidin-5-yl]-3-(3,4,5-trimethoxy phenyl)-prop-2-en-1-one (4c)

Yield: 85%. m.p. 227-229°C. IR(KBr)v(cm⁻¹):3369 (NH), 2986(CH-aliphatic),3195 (CH-aromatic), 1687 (C=O). MS (E1) m/z: 467(M⁺, 63%). ¹H precipitate was filtered off, dried and recrystallized from aqueous DMF to give compounds **5a-d**.

6-[4-(4-Dimethylaminophenyl)-6-methyl-2-thioxo-1,2,3,4-tetrahydropyrimidin-5-yl]-2-oxo-4-phenyl-1,2-dihydro-pyridine-3- carbonitrile (5a)

Yield: 84%. m.p. 260-262°C. IR (KBr) v (cm⁻¹): 3355 (NH), 2987(CH-aliphatic), 2220(CN), 3177 (CH-aromatic), 1686 (C=O). MS (E1) m/z: 441

(M⁺,77%). ¹H NMR (DMSO-d₆, 300MHz) δ (ppm):2.26 (s,3H, CH₃, pyrimidine), 2.5 (s,6H, 2CH₃), 5.2(s,1H, pyrimidine), 7-7.8 (m,9H , Ar-H),8.3(s,1H ,pyridone), 9.6, 9.8,10.2 (s,3H, 3NH, D₂O exchangeable) . ¹³CNMR (300 MHz, DMSO-d₆):178.0(C=S) , 162.0 (C=O) , 138.0 (C, C-6) , 112.0(C,C-5),112.0,126.2, 127.2, 128.2, 128.0, 131.0 , 134.2, 142.0(Ar/ olefinic carbon), 95.0, 104.0, 137.0, 169.0 (CH pyridone) ,117.0 (CN),54.0(C, C-4), 40.6(NCH₃), 18.0(CH₃). Anal. Calcd for C₂₅H₂₃N₅OS (441.55):C, 68.00;H, 5.25;N,15.86;S,7.26%. Found: C, 68.05; H,5.29; N,15.89;S,7.24%.

6-[4-(4-Dimethylaminophenyl)-6-methyl-2- thioxo-1,2,3,4-tetrahydropyrimidin-5-yl]-4-(4-methoxyphenyl)-2-oxo-1,2-dihydro-pyridine-3-carbonitrile (5b)

Yield:87%. m.p. 251-252°C. IR(KBr) v(cm⁻¹): 3356(NH),2977(CH-aliphatic), 2225(CN), 3178 (CH-aromatic). 1688(C=O). MS (E1) m/z: 471 (M⁺, 71%). ¹H NMR (DMSO-d₆, 300MHz)δ (ppm): 2.25 (s,3H,CH₃,pyrimidine), 2.5(s,6H, 2CH₃), 4.1 (s,3H,OCH₃), 5.1 (s,1H,pyrimidine), 7-7.9 (m,8H , Ar-H),8.2(s,1H, pyridone), 9.7, 9.8, 10.2 (s,3H, 3NH, D₂O exchangeable). ¹³C NMR (300 MHz, DMSO-d₆): 178.0 (C=S), 162.0 (C=O),138.2(C,

63.26;H, 5.50;N,13.17;S, 6.03%. Found C, 63.39;H, 5.43;N,13.28;S, 6.17%.

4-(4-Dimethylamino phenyl)-6-[4-(4-Dimethyl amino phenyl)- 6-methyl-2-thioxo-1,2,3,4-tetra hydropyrimidin-5-yl]-2-oxo-1,2-dihydro- pyridine-3-carbonitrile (5d)

Yield: 74%. m.p. 270-272°C. IR(KBr)v(cm⁻¹):3376 (NH),2978(CH-aliphatic),2221 (CN), 3188(CH-aromatic) ,1680(C=O). MS (E1) m/z: 484(M⁺, 80%). ¹H NMR (DMSO-d₆, 300 MHz) δ (ppm): 2.23 (s, 3H, CH₃, pyrimidine), 2.4,2.53(s,12H, 4CH₃),5.1 (s,1H, pyrimidine), 7.2-7.8 (m,8H,Ar-H),8.2(s,1H ,pyridone) , 9.7,9.9,10.2 (s, 3H, 3NH, D₂O exchangeable). ¹³C NMR (300 MHz, DMSO- d₆): 178.8 (C=S) , 162.0 (C=O) , 138.0(C, C-6) , 112.0(C, C-5),112.0, 113.0,124.0, 127.0, 128.1, 131.1, 142.0 ,143.0 (Ar/olefinic carbon), 95.0, 104.0,137.3, 169.6(CH pyridone) ,117.0 (CN), 56.3, 56.6 (OCH₃),54.4(C, C-4), 40.6 (NCH₃), 18.0(CH₃). Anal. Calcd for C₂₇H₂₈N₆ OS(484.61): C, 66.92;H, 5.82; N,17.34;S, 6.62%. Found C, 66.97;H, 5.77;N,17.45;S, 6.59%.

General procedure for preparation of compound 6

A mixture of **1** (0.001 mole),malononitrile or ethyl cyanoacetate (0.001 mole) in presence of catalytic amount of triethylamine (4drops) was refluxed for 6 - 8 h, then cooled, poured on ice/water and neutralized

C-6),112.2 (C ,C-5), 112.1, 114.5, 120.5, 127.5, 128.5 , 128.0, 131.1, 142.0, 159.5(Ar/olefinic carbon), 95.0,104.0, 137.3 , 169.6(CH pyridone) ,117.0(CN), 56.2 (OCH₃), 54.0 (C, C-4), 40.0 (NCH₃), 18.2(CH₃).Anal. Calcd for C₂₆H₂₅N₅O₂S (471.57): C, 66.22;H, 5.34;N, 14.85; S, 6.80%. Found: C, 66.29; H, 5.44;N,14.78;S, 6.82%.

6-[4-(4-Dimethylaminophenyl)-6-methyl-2- thioxo-1,2,3,4-tetrahydropyrimidin-5-yl]-2- oxo-4-(3,4,5-trimethoxy-phenyl)-1,2-dihydro- pyridine-3-carbonitrile (5c)

Yield: 72%. m.p. 240-242°C. IR(KBr) v(cm⁻¹): 3366(NH),2959(CH-aliphatic), 2209 (CN), 3069 (CH-aromatic). 1689(C=O). MS (E1) m/z: 531(M⁺, 83%). ¹H NMR (DMSO-d₆, 300MHz)δ (ppm): 2.21 (s,3H,CH₃,pyrimidine), 2.50(s,6H, 2CH₃), 3.33, 3.82,3.86(s, 9H,3OCH₃),5.21(s,1H pyrimidine),6.99-7.88 (m, 6H ,Ar-H), 7.90(s,1H, pyridone) 9.0,10.0 (s,3H,3NH, D₂O exchan - geable) . ¹³C NMR (300 MHz, DMSO-d₆): 178.7 (C=S) , 163.3(C=O) , 139.9(C, C-6) , 114.8(C, C-5),102.6, 112.6,127.6, 126.8, 128.5, 142.9, 148.7,150.5(Ar/olefinic carbon),97.3, 107.6 , 137.6, 169.1(CH pyridone) ,118.6(CN), 56.4, 56.6 (OCH₃),55.9(C, C-4), 40.2(NCH₃), 18.5 (CH₃).Anal. Calcd for C₂₈H₂₉ N₅O₄S (531.62): C,

2-Cyano-3-[4-(4(dimethylaminophenyl)-6- methyl-2-thioxo-1,2,3,4-tetrahydro pyrimidine -5-yl]-but-2-enoate (6b)

Yield:70%. m.p. 150-152°C. IR (KBr) v (cm⁻¹): 3390(NH),2926(CH-aliphatic),3063(CH-aromatic) . 2225 (CN) ,1704(C=O). MS (E1) m/z: 384(M⁺, 66%). ¹H NMR (DMSO-d₆, 300MHz) δ (ppm): 2.0(t,3H, CH₃), 2.25(s,3H,CH₃,pyrimidine), 2.46 (s,3H,CH₃),2.50 (s,6H,2CH₃),3.86(q,2H, CH₂),5.2 (s,1H pyrimid ine), 7.13-7.52(md,4H,aromatic), 9.6,9.9(s, 2H, NH pyrimidine,D₂O exchangeable). ¹³C NMR (300 MHz, DMSO-d₆):180.0(C=S) , 169.3(CH),165.6(C=O), 111.9(C, C-5) ,138.0(C, C-6) ,113.9, 127.3,128.1.1, 145.3(Ar/ olefinic carbon),118.6(CN),94.3(CH), 56.0(CH₂),55.0 (C, C-4) , 40.4(NCH₃) , 12.6,14.9, 18.0 (CH₃). Anal. Calcd for C₂₀H₂₄N₄ O₂S(384.49): C, 62.48;H, 6.29;N,14.57;S, 8.34%. Found: C, 62.57;H, 6.34;N,14.61;S, 8.36%.

with dil. HCl, the produced precipitate was filtered off, dried under suction and recrystallized from DMF/ water to give **6 a, b**.

2-[1-[4-(4-Dimethylaminopheny)-6-methyl-2- thioxo-1,2,3,4-tetrahydropyrimidin-5-yl]ethyl idene]- malonitrile (6a)

Yield: 67%. m.p. 180-2°C. IR(KBr) v (cm⁻¹):3357 (NH), 2988(CH-aliphatic), 3176(CH-aromatic),

2226(CN). MS(E1) m/z: 377(M⁺, 67%). ¹H NMR (DMSO-d₆, 300MHz) δ (ppm): 2.24 (s, 3H, CH₃, pyrimidine), 2.4 (s, 3H, CH₃), 2.5 (s, 6H, 2CH₃), 5.1 (s, 1H Pyrimidine), 7.2-7.6 (m, 4H, Ar-H), 9.6, 9.8 (s, 2H, NH, pyrimidine D₂O exchangeable). ¹³C NMR (300 MHz, DMSO-d₆): 178.0 (C=S), 174.0 (CH), 112.2 (C, C-5), 138.0 (C, C-6), 112.0, 128.0, 131.0, 142.2 (Ar/olefinic carbon), 117.0 (CN), 74.0 (CH), 55.0 (C, C-4), 40.6 (NCH₃), 12.0, 18.0 (CH₃). Anal. Calcd for C₁₈H₁₉N₅S (337.44): C, 64.07; H, 5.68; N, 20.75; S, 9.50%. Found C, 64.17; H, 5.74; N, 20.77; S, 9.49%.

General procedure for preparation of compound 7

To a suspension of the methyl ketone **1** (0.1 mol), malononitrile or ethyl cyanoacetate (0.1 mol) and 3.2 g sulfur in 30 ml ethanol, diethylamine (0.1 mol) was added drop wise for 30 m and the reaction mixture was heated (70°C) under stirring in absolute ethanol for 4-6 h. mixture was left for 24 h at 0°C. The obtained 2-aminothiophene crystalized in the form of yellow powder. The precipitate was filtrated, washed with water and recrystallized from ethanol to give **7a**, **b**.

2-Amino-4-[4-(4-dimethylaminophenyl)-6-methyl-2-thioxo-1,2,3,4-tetrahydropyrimidine-5-yl]-thiophene-3-carbonitrile (7a)

Yield: 67%. m.p. 130-132°C. IR(KBr)ν(cm⁻¹): 3257 (NH), 2980 (CH-aliphatic), 3176 (CH-aromatic), 2222 (CN). MS(E1) m/z: 369(M⁺, 67%). ¹H NMR (DMSO-d₆, 300MHz) δ(ppm): 2.20 (s, 3H, CH₃, pyrimidine), 2.5 (s, 6H, 2CH₃), 4.08 (s, 2H, NH₂, D₂O exchangeable), 5.1 (s, 1H pyrimidine), 7.4-7.54 (m, 5H, Ar-H), 9.9.5 (s, 2H, NH, pyrimidine D₂O exchangeable). ¹³C NMR (300 MHz, DMSO-d₆): 178.0 (C=S), 111.0 (C, C-5), 140.0 (C, C-6), 110.0, 112.2, 123.0, 128.2, 131.1, 137.0, 138.0, 142.1 (Ar/olefinic carbon), 116.0 (CN), 61.0 (C, C-4), 40.0 (NCH₃), 18.0 (CH₃). Anal. Calcd for C₁₈H₁₉N₅S₂ (369.51): C, 58.51; H, 5.18; N, 18.95; S, 17.36%. Found: C, 58.58; H, 5.17; N, 18.90; S, 17.32%.

used as analytical grade, and were purchased from Sigma-Aldrich Chemicals Co., St. Louis, MO, USA.

2-Amino-4-[4-(4-dimethylaminophenyl)-6-methyl-2-thioxo-1,2,3,4-tetrahydro pyrimidine-5-yl]-thiophene-3-ethanoate (7b)

Yield: 60%. m.p. 150-152°C. IR(KBr)ν(cm⁻¹): 3318 (NH), 2936 (CH-aliphatic), 3198 (CH-aromatic), 1736 (C=O). MS (E1) m/z: 416(M⁺, 66%). ¹H NMR (DMSO-d₆, 300MHz) δ (ppm): 1.29 (t, 3H, CH₃), 2.48 (s, 3H, CH₃, pyrimidine), 2.50 (s, 6H, 2CH₃), 3.08 (q, 2H, CH₂), 3.36 (s, 2H, NH₂, D₂O exchangeable), 5.2 (s, 1H pyrimidine), 6.82-8.09 (m, 5H, aromatic), 9.0, 10.0 (s, 2H, NH pyrimidine, D₂O exchangeable). ¹³C NMR (300 MHz, DMSO-d₆): 178.8 (C=S), 160.5 (C=O), 114.8 (C, C-5), 139.9 (C, C-6), 118.6, 127.6, 128.0, 128.7, 128.9, 130.0, 148.7 (Ar/olefinic carbon), 63.3 (C, C-4), 55.9 (CH₂), 40.6 (NCH₃), 13.1, 18.3 (CH₃). Anal. Calcd for C₂₀H₂₄N₄O₂S₂ (416.56): C, 57.67; H, 5.81; N, 13.45; S, 15.40%. Found: C, 57.65; H, 5.87; N, 13.40; S, 15.44%.

2.2.1 Biological assay

2.2.1.1 Anti-inflammatory activity

Chemicals: All chemicals required for assay were

Animals: Adult male Sprague-Dawley rats (5 rats per group), weighing 120-150 g, were housed in polyethylene cages in a temperature-controlled (25 ± 1°C) environment and provided free access to food and purified drinking water.

Carrageenan-induced mouse paw edema: The anti-inflammatory activity was performed according to Winter et al. [39] prepared compounds (equimolar to active dose of the reference drug), control and standard drug were dissolved in 1 ml DMSO and administrated subcutaneously. One hour later, paw oedema was induced by sub-plantar injection of 0.1 ml of 1% carrageenan (Sigma-Aldrich, St. Louis, USA) in distilled water into the right paw. The paw volumes were measured using a water plethysmometer (Basile, Comerio, Italy) before and after injection of 1% carrageenan at different time intervals (1, 2, 3 and 4 h). The difference between the right and left paw volume was measured at the above-mentioned time intervals after induction of inflammation. Control group (five rats per group) received 1 ml DMSO (as to evaluate the interference of DMSO itself in biological test) subcutaneously and carrageenan in sub-plantar region.

Results were expressed as percentage inhibition of inflammation. Ibuprofen (70 mg kg⁻¹) was used as the reference drug (Table 1).

Statistical Analysis: Results are expressed as the mean \pm SEM, and different groups were compared using one way analysis of variance (ANOVA) followed by Tukey–Kramer test for multiple comparisons, using Graph Pad Instant (version 3.05) as the statistical software.

Calculation: Equimolar doses of tested compounds were calculated in relation to these of reference drug:

Swell = mean difference in rat paw volume between right and left paw \pm SE.

$$\% \text{ inhibition} = (1 - rt/rc) \times 100$$

[rt = swell of tested group; rc = swell of control group].

2.2.2 Biochemical assay

2.2.2.1 *In vitro* cyclooxygenase inhibition assay

Drugs capacities to inhibit COX-1 and COX-2

assay buffer, 10 ml of heme, and 10 ml of ovine COX- 1 or COX- 2 showed 100% initial activity as a control experiment in the absence of inhibitor. Celecoxib, Ibuprofen were used as reference standards in the study. The assays were performed in triplicate, and the IC₅₀ values were calculated from the concentration curves by means of Graph Pad software PRISM.

2.2.3 Molecular modeling procedure

All Molecular modelling work was performed using SYBYL-X package (www.certara.com). Protein co-crystal structure was downloaded from the protein databank (PDB) database (www.rcsb.org). The protein was first optimized for docking by deleting all but one monomer in the quaternary structures. Next, the protein was prepared using “Prepare Protein” tool embedded in the Sybyl-X program. Ligands were converted to 3D structures and prepared using Concord module embedded in Sybyl-X’s prepare ligands tool.

The prepared protein and ligand structures were then used for molecular docking using Surflex docking engine. A hypothetical protomol was generated to define the shape and features of the binding site using the binding mode of the co-crystallized ligand.

enzymes were assessed using ELISA kits; Cayman colorimetric COX (ovine) inhibitor screening assay kit [40] (Catalog No. 760111) supplied by Cayman chemicals, Ann Arbor, MI, USA. The used protocol was according to the manufacturer protocol guide and instructions using ELISA plate reader.

The inhibitory COX activity of the most active tested compounds and the reference was assayed using Cayman colorimetric COX (ovine) inhibitor screening assay kit (Catalog No. 760111, Cayman Chemicals, Ann Arbor, MI) according to the manufacturer’s instructions. Aliquots (170 ml) of the assay buffer (0.1N Tris– HCl, pH 8.0), heme, and enzyme ovine (COX- 1 or COX- 2) were placed in a 96-well plate. The compounds were added to the aliquots. The plate was shaken for a few seconds and then incubated for 5 m at 25°C. The colorimetric substrate N, N, N', N'-tetramethyl-p-phenylene diamine (20 ml, TMPD) and arachidonic acid (20 ml) were added to the aliquots. The plate was carefully shaken for a few seconds and then incubated for 5 m at 25°C. The absorbance was measured at 590 nm using a 96- well Tecan Safire plate reader. The mixture of 160 ml of assay buffer and 10 ml of heme served as a back-ground control. The mixture of 150 ml of

Docking results were analyzed using the analyze results tool in Sybyl- X.

3. RESULTS AND DISCUSSION

3.1 Chemistry

The synthetic route utilized for the synthesis of the target compounds is outlined in Schemes 1 and 2. 2-Thioxo-1,2,3,4-tetrahydropyrimidine derivative **1** was achieved by direct Biginelli condensation using ethyl acetoacetate, thiourea and N,N-dimethyl benzaldehyde in ethanol and few drops of HCl [38]. Biginelli method remains one of the most synthetic methods for preparation of pyrimidine derivatives [41,42]. It is a multiple component chemical reaction involves an aldol condensation of acetyl acetone and the aryl aldehyde which is the rate limiting step leading to the carbenium ion. The nucleophilic addition of thiourea gives intermediate, which quickly dehydrates to give the desired compound. Pyrimidine-2- thione **1** was used as asynthon for other pyrimidine derivatives. New Schiff bases **2a-d** have been synthesized from the condensation of various aromatic amines with methyl ketone **1** in the presence of a

catalytic amount of conc.H₂SO₄ [43-45]. An imine, a compound in which the C = O double bond is replaced by a C = N double bond. This type of compound is known as an imine or Schiff base (azomethines). The IR spectra of **2a-d** revealed the absence of the absorption bands corresponding to the C=O group and the detection of a strong C=N stretching band at 1580-1600 cm⁻¹ evidenced the formation of the Schiff base. Their ¹H-NMR showed singlet at 8.8-

11.6 ppm corresponding to the D₂O exchangeable protons of 2NH of the pyrimidine ring. Pyrimidine-2-thione **1** undergoes Mannich reaction [46,47] with paraformaldehyde and certain primary aromatic amines yielding compounds **3a-d**. The mechanism of Mannich reaction starts with the formation of an iminium ion from the amine and the formaldehyde. The ketone can tautomerize to the enol form, after which it can attack the iminium ion. The final product is a β-amino-carbonyl compound also known as a Mannich base as exemplified by compounds **3a-d** [Fig. 3]. Their IR spectra showed the presence of absorption bands at 1681-1689 cm⁻¹ characteristic for the C=O groups. Their ¹H-NMR spectra showed triplets of CH₂-CH₂ at the range 3.03-3.34 ppm.

α,β-Unsaturated compounds **4a-d** (Chalcones) were prepared via Claisen-Schmidt condensation of methyl ketone **1** and substituted benzaldehyde in basic medium [48]. Their IR spectra showed absorption bands at the carbonyl region 1675-1687 cm⁻¹. ¹H-NMR spectra showed the doublet-doublet corresponding to CH=CH of the chalcones. Pyridones **5a-d** were also prepared through one pot multicomponent reaction of methyl ketone **1**, an aldehyde, ethyl cyanoacetate and excess ammonium acetate in basic medium [49]. Their IR spectra revealed the appearance of the bands corresponding to CN around 2200 cm⁻¹, NH around 3350 cm⁻¹ and C=O around 1680 cm⁻¹. The ¹H-NMR spectra showed the disappearance of the singlet corresponding to COCH₃ (Schemes 1). On the other hand, when methyl ketone **1** was condensed with malononitrile [50] or ethyl cyanoacetate in presence of catalytic amount of triethylamine, they give derivatives **6a** and **b**, respectively. The IR spectrum of **6a** revealed the absence of C=O groups and the appearance of the bands corresponding to CN at 2226 cm⁻¹. While the ¹H-NMR spectrum of **6b** showed triplet signal at 2 ppm and quartet signals at 3.8 ppm of COOC₂H₅. Finally, 2-amino thiophene derivatives **7a** and **7b** were synthesized through Gewald thiophene [51] synthesis via a Knoevenagel

condensation between methyl ketone **1** and ethyl cyanoacetate or malononitrile **2** to produce the stable intermediate **3**. The mechanism of the addition of sulphur is unknown. It is postulated to proceed through intermediate **4**. Cyclization and tautomerism will produce the desired product **6** [Fig. 4]. The IR spectrum of **7a** revealed the

absence of the absorption bands of the C=O group and the appearance of the bands of CN. The ¹H-NMR spectra for **7a** and **b** showed singlet of the NH₂ protons at the range 3.36-4.08 ppm (Schemes 2). The structures of new compounds were assigned by MS, IR, ¹H-NMR, ¹³C-NMR, as well as elemental analysis.




Fig. 3.Synthetic and mechanistic pathway for preparation of thiopyrimidines 3 a-d





Fig. 4.Synthetic and mechanistic pathway for preparation of thiopyrimidines 7a,b




Scheme 1. Synthesis of the designed compounds (4a-t)

3.2 Anti-inflammatory Evaluation

All compounds were examined for their anti-inflammatory activity using the carrageenan-induced rat paw edema assay in comparison to ibuprofen, as a reference drug [Fig. 5]. According to the data results expressed in %protection; shown in Table 1, Compound **3c** (86%) showed the best % inhibition against Carrageenan-induced paw edema in rats at 4h to be more than that was shown by ibuprofen (69%). Interestingly, the results went aligned with what we got from the *in vitro* testing against COX-1 and COX-2 enzymatic assay (Table 2). Compounds **2a-d**, **3a-d**, **7a**, **7b** induced strong anti-inflammatory activity, comparable with that of ibuprofen, they showed significantly difference at 4h post-carrageenan and **2b**, **2c**, **3c** and **7a** have the same activity profile as ibuprofen (response increase by time). Compounds **2a**, **3d** and **7a**

exerted good anti-inflammatory activity than ibuprofen at 3 h interval post-carrageenan. The compounds produced 76, 66, and 65% inhibition respectively, compared to 60% inhibition for ibuprofen. Compounds **2c**, **3b**, **3c**, **6b** and **7a** showed higher anti-inflammatory activities than ibuprofen at 1 hr interval post-carrageenan range from 22-74%. Compounds **1**, **2a**, **2d**, **3d**, **6a**, **7b** showed no anti-inflammatory activity at 1st and 2nd h interval post-carrageenan. Yet, they exerted from moderate to good anti-inflammatory activities at 4th h interval post-carrageenan. Compound **3a** had no anti-inflammatory activity at 1h post-carrageenan and showed moderate anti-inflammatory activity at 2nd and 3rd h and good activity at 4th h post-carrageenan. Compounds **4a-d** and **5a-d** were all inactive over all tested periods, showing % inhibition < 10, 18, 20 and 31 at 1st to 4th h, respectively, and were indicated as inactive in Table 1.



Scheme 2. Synthesis of the designed compounds (6,7a-b)

3.2.1 Structure-activity Relationships (SAR)

To analyze our structure-activity relationships, Regarding the nature of the aromatic nucleus in the side chain at C-5, the presence of acetyl group at para-position in the side chain at C-5 in compounds **2c**, **3c** has higher anti-inflammatory activity (78, 86%) during the 4th hour post-

carrageenan than the methyl group at ortho- position in compounds **2b**, **3b** and the chloro group at para - position in compounds **2d,3d** during the 4th hour post-carrageenan. The presence of this group may be making these compounds favorable stereochemically and electronically for interaction with the active site and thus showing good anti-inflammatory activity.




Fig. 5. *In vivo* anti-inflammatory effect (% Inhibition) of the tested compounds compared to the reference drug (ibuprofen)

Table 1. *In vivo* anti-inflammatory activity against carrageenan-induced paw edema in rats edema

Compounds	induced by carrageenan (% edema inhibition relative to control) ^a			
	1h	2 h	3 h	4 h
	mean ± SEM (% inh.)	mean ± SEM (% inh.)	mean ± SEM (% inh.)	mean ± SEM (% inh.)
1	0.24±0.005 (-)	0.26±0.002 (-)	0.15±0.046 (72)	0.24±0.125 (61)
2a	0.22±0.003 (-)	0.26±0.008 (-)	0.13±0.036 (76)	0.155±0.051(75**)
2b	0.23±0.005 (-)	0.21±0.033(19)	0.24±0.057 (56)	0.17±0.137 (73**)
2c	0.17±0.003(26)	0.16±0.005(38)	0.25±0.005 (54)	0.136±0.03 (78***)
2d	0.23±0.001 (-)	0.26±0.001 (-)	0.23±0.006 (57)	0.173±0.123(72**)
3a	0.24±0.007 (-)	0.169±0.023(35)	0.297±0.021(45)	0.142±0.180(77***)
3b	0.06±0.31(74)	0.16±0.013 (38)	0.31±0.106 (43)	0.148±0.055(76***)
3c	0.18±0.036(22)	0.14±0.045(46)	0.24±0.124 (55)	0.086±0.124(86***)
3d	0.23±0.13 (-)	0.26±0.003 (-)	0.185±0.014(66)	0.16±0.035 (74**)
6a	0.24±0.003 (-)	0.26±0.005 (-)	0.24±0.033 (56)	0.198±0.090(68**)
6b	0.13±0.032(43)	0.22±0.013(15)	0.2±0.081 (63)	0.201±0.03 (66**)
7a	0.16±0.020(30)	0.15±0.004(42)	0.19±0.080 (65)	0.173±0.01 (72***)
7b	0.23±0.003 (-)	0.26±0.005 (-)	0.31±0.081 (42)	0.167±0.013 (73**)
Ibuprofen	0.215±0.022(6)	0.14±0.054(46)	0.214±0.017(60)	0.193±0.015 (69*)
Control	0.23±0.048 (-)	0.26±0.038 (-)	0.54±0.08 (-)	0.62±0.03 (-)

^a solvent: 2.5 mL DMSO. Dose: 70 mg kg⁻¹ ibuprofen and the equivalent amount of tested compounds.

SEM: standard error of the mean.

%inhibition = $(1-rt/rc) \times 100$ [rt= mean of tested group; rc= mean of control group]

* Significantly different compared to control at respective time point at $p < 0.05$

**Significantly different compared to ibuprofen at respective time point at $p < 0.05$

3.3 *In vitro* Cyclooxygenase (COX) Inhibition Assay

The compounds **1**, **2c** and **3c** were subjected to enzyme assay investigations against COX-1, and COX-2. Results for the *in vitro* enzyme inhibition assays, displayed in Table 2, revealed that compounds **1**, **2c** and **3c** showed higher potency towards COX-2 over COX-1. Compound **3c** realized higher potency towards COX-2 (IC₅₀ = 0.046 μ M) than compounds **1** (IC₅₀ = 0.21 μ M) and **2c** (IC₅₀ = 0.11 μ M) as well as celecoxib and ibuprofen (IC₅₀ = 0.045, 43.628 μ M, respectively).

Further investigation of the *in vitro* results revealed that the highest *in vitro* anti-inflammatory activity of compound **3c** might be attributed to presence of acetyl group that would increase binding interaction to COX-2 enzyme through hydrogen bond interaction.

3.4 Molecular Modeling

Molecular docking studies were carried out using SYBLYL-X v.2.1 software. Crystal structures from the Protein Databank website (www.rcsb.) were downloaded. Protocol described in the “Experimental” section.

To propose an understanding of the anti-inflammatory and the enzyme inhibition assay results on a structural basis, docking of selected compounds into the active site of COX-2 was conducted. The flexible docking calculations give a prediction for correct binding geometry for each binder. The scoring functions and hydrogen bonds formed with the amino acids of the receptor. Three compounds which score significant anti-inflammatory activates **1,2c** and **3c** were docked into the active site of COX-2 enzyme. The Docking scores of the compounds were calculated from minimized ligand protein complexes, hydrogen bond distances are shown in Table 3. Results of their interaction energies with COX-2 enzyme revealed that tested compounds **2c**, **3c** and **7a** showed proper fitting to the active site of COX-2 enzyme, scoring bond energies ranging from -3.6329 to 6.0459 Kcal/mol compared to 9.0092 for Ibuprofen reference drug. The crystal structure of compound **1** in complex with COX-2 shows no hydrogen bonding between the compound and any of the binding site residues. Binding however could be explained on the bases of extensive Van Der Waals contact with many hydrophobic residues which include Trp388, Tyr386, Phe519, Met523, Leu532, Val117, Leu360 and Val350

[Fig. 6]. Compound **2c** forms 2 hydrogen bonds with the guanido side chain of Arg514. Significant hydrophobic contact is found between the pyrimidine thione moiety of the compound with the side chains of Trp388, Tyr386, Phe519 and Met523. Furthermore, the side chains of Leu532, Val117, Leu360 and Val350 with the N,N-

dimethylaniline moiety also show hydrophobic contact [Fig. 7]. The orientation of the most active compound **3c** is quite similar to that of **2c** [Fig. 8]. The Surflex Score values show good agreement with binding affinities obtained by docking studies as verified by pharmacological testing.

Table 2. *In vitro* COX-1 and COX-2 enzymes inhibitory activities, IC50 values of the tested compounds

Compound	COX-1 IC50 (μm) ^a	COX-2 IC50 (μm)
Celecoxib	14.7	0.045
Ibuprofen	31.954	43.628
1	5.41	0.21
2c	9.11	0.11
3c	12.6	0.046

^a Values are means of three determinations

Table 3. Molecular docking results of active compounds into COX-2 enzyme using SYBLYL- X.2.1

Compounds	Surflex Score	N ^o of Hydrogen Bonds
Ibuprofen	9.0092	3
1	5.5331	0
2a	-0.2735	1
2b	2.9907	1
2c	-3.6329	2
2d	1.5165	0
3a	7.2142	0
3b	5.9312	1
3c	6.0459	2
3d	5.1953	1
6a	0.8744	1
6b	0.5471	1
7a	2.8091	2
7b	3.3581	1

Surflex score = Calculated $-\log K_d$




Fig. 6. Binding mode of compound 1 into binding site of COX-II, Showing extensive Vander Waals contact with many hydrophobic residues which include Trp388, Tyr386, Phe519, Met523, Leu532, Val117, Leu360 and Val350




Fig. 7. Binding mode of compound 2c into binding site of COX-II, Showing two H-bonds with the guanido side chain of Arg514. Significant hydrophobic contact is found between the pyrimidine thione moiety of the compound with the side chains of Trp388, Tyr386, Phe519 and Met523. Furthermore, the side chains of Leu532, Val117, Leu360 and Val350 with the N,N- dimethylaniline moiety also show hydrophobic contact




Fig. 8. Binding mode of compound 3c into binding site of COX-II, Showing two H-bonds with the guanido side chain of Arg514. Significant hydrophobic contact is found between the pyrimidine thione moiety of the compound with the side chains of Trp388, Tyr386, Phe519 and Met523. Hydrophobic contact is also found between the side chains of Leu532, Val117, Leu360 and Val350 with and the N,N- dimethylaniline moiety

4. CONCLUSIONS

In summary, we have synthesized a series of new pyrimidine derivatives (**2a-d-7a-b**) by a simple and available method leads to a molecule of promising anti-inflammatory activity. *In vivo* anti-inflammatory assay revealed that compounds **2a-d**, **3a-d**, **7a**, **7b** induced strong anti-inflammatory activity, comparable with that of ibuprofen, were significantly difference at 4 h post-carrageenan and **2b**, **2c**, **3c** and **7a** have the same activity profile as ibuprofen (response increase by time). Compound **3c** (86%) showed the best % inhibition against Carrageenan-induced paw edema in rats at 4 h to be more than that was shown by ibuprofen (69%). Interestingly, the results went aligned with what we got from the *in vitro* testing against COX-1 and COX-2 enzymatic assay. To analyze our structure-activity relationships, the presence of acetyl group at Para-position in the side chain at C-5 in compounds **2c**, **3c** gives promising anti-inflammatory activity (78, 86%). Compound **3c** realized higher potency towards COX-2 (IC_{50} = 0.046 μ M) than compounds **1** (IC_{50} = 0.21 μ M) and **2c** (IC_{50} = 0.11 μ M) as well as celecoxib and ibuprofen (IC_{50} = 0.045 and 43.628 μ M, respectively). The Surfex Score values show good agreement with binding affinities obtained by docking studies as verified by pharmacological testing. Further research is recommended to approve the importance of new derivatives for various applications.

CONSENT

It is not applicable.

ETHICAL APPROVAL

All authors hereby declare that "Principles of laboratory animal care" (NIH PUBLICATION NO. 85-23, REVISED IN 1996) were followed, as well as specific national laws where applicable. All experiments have been examined and approved by the appropriate ethics committee.

ACKNOWLEDGEMENT

Authors thank colleagues from Faculty of Pharmacy, Helwan University for help and support. We especially thank Moustafa E. El-Araby (Professor of Pharmaceutical Organic Chemistry, Faculty of Pharmacy, Helwan University) for his generous help, valuable advice and all facilities for molecular docking study in this research. Moreover, the authors would like to

thank for Mossad Sayed Mohamed (Professor of Pharmaceutical Organic Chemistry) for his inspiration and support.

COMPETING INTERESTS

Authors have declared that no competing interests exist.

REFERENCES

1. Rakesh RC, Kallappa MH, Badarinath DK, Shrinivas DJ. Molecular docking studies and facile synthesis of most potent biologically active N -tert -butyl-4-(4-substituted phenyl)-2- ((substituted-2-oxo-2H-chromen-4-yl)methylthio)-6-oxo-1,6-dihydropyrimidine-5-carboxamide hybrids: An approach for microwave-assisted syntheses and biological evaluation. *Bioorg Chem.* 2018;78:185-94.
2. Maja SB, Ana R, Marijana J, Ljubica GO, Domagoj D, Silvana, RM, et al. Synthesis, cytostatic and antibacterial evaluations of novel 1,2,3 - triazolyl- tagged pyrimidine and furo [2,3- d] pyrimidine derivatives. *Croat Chem Acta.* 2017;90(2):197- 205.
3. Ruofeng S, Yunpeng Y, Chao Z, Yunxing F, Jianping L, Wanxia P. Antibacterial activity and pharmacokinetic profile of a promising antibacterial agent: 14- O-[(4- Amino-6-hydroxy-pyrimidine-2-yl) thio acetyl]mutilin. *Pharma Research.* 2018; 129:424-31.
4. Han-Bo L, Wei-Wei G, Vijai KRT, Cheng- He ZRG. Novel aminopyrimidinyl benzimidazoles as potentially antimicrobial agents: Design, synthesis and biological evaluation. *Eur J Med Chem.* 2018;143: 66-84.
5. Nagaraju M, Sunandamma Y, Manojit P. 1,2,3-Triazole fused with pyridine/ pyrimidine as new template for antimicrobial agents: Regioselective synthesis and identification of potent N - heteroarenes. *Bioorg & Med Chem Lett.* 2018;28:3302-6.
6. Mostafa S, Adel MKE, Mostafa A, Reda H. Design, synthesis and characterization of novel pyrimidines bearing indole as antimicrobial agents. *J Chin Chem Soc.* 2018;1-8.
7. Mahesh MP, Laxman UN, Manoj DP, Sujit GB, Jayant MG, Dhiman S, et al. Hybrids of thieno pyrimidinones and thiouracils as anti-tubercular agents: SAR and docking

- studies. *Eur J Med Chem.* 2017;127:459- 69.
8. Guonan C, Jing J, Hualong C, Ran C, Xiaoguang C, Bailing X. Synthesis and biological evaluation of pyrimidine derivatives as novel human Pin1 inhibitors. *Bioorg & Med Chem.* 2018;26: 2186-97.
 9. Wuji S, Shengquan H, Shubiao F, Hong Y. Design, synthesis and biological evaluation of pyrimidine-based derivatives as VEGFR-2 tyrosine kinase inhibitors. *Bioorg Chem.* 2018;78:393-405.
 10. Kai JJ, Hong Y, Erik DC, Christophe P, Ge M, Fen EC. Discovery of biphenyl-substituted diarylpyrimidines as non-nucleoside reverse transcriptase inhibitors with high potency against wild-type and mutant HIV-1. *Eur J Med Chem.* 2018;145:726-34.
 11. Kai JJ, Ya LS, Erik DC, Christophe P, Ge M. Design and synthesis of a novel series of non-nucleoside HIV-1 inhibitors bearing pyrimidine and N-substituted aromatic piperazine. *Bioorg & Med Chem Lett.* 2018;28:3491-95.
 12. Joana F, Joao LS, Eunice C, Leena K, Jari Y, Vania MM, et al. Trisubstituted barbiturates and thiobarbiturates: Synthesis and biological evaluation as xanthine oxidase inhibitors, antioxidants, antibacterial and anti-proliferative agents. *Eur J Med Chem.* 2018;143:829-42.
 13. Méndez-Arriaga JM, Oyarzabal I, Escolano G, Rodríguez-Diéguez A, Sánchez-Moreno M, Salas JM. *In vitro* leishmanicidal and trypanocidal evaluation and magnetic properties of 7-amino-1,2,4-triazolo[1,5-a]pyrimidine Cu(II) complexes. *J Inorg Biochem.* 2018;180:26-32.
 14. Alexandra MT, Hiba AA, Patrick GN, Carroll BH, Mark NP, Peter W, et al. Dihydropyrimidinones and -thiones with improved activity against human polyomavirus family members. *Bioorg & Med Chem Lett.* 2016;26:5087-91.
 15. Song B, Shan L, Yunying Z, Qin W. Asymmetric synthesis and antiviral activity of novel chiral amino-pyrimidine derivatives. *Tetrahedron Lett.* 2018;59: 3179-83.
 16. Adel AA, Abd-Allah SE, Ahmed ESA, Megied IFZ, El Sayed HE. Synthesis and antiviral evaluation of novel 2,3-dihydroxypropyl nucleosides from 2- and 4- Thiouracils. *Nucleosides Nucleotides and Nucleic Acids.* 2008;27:1257-71.
 17. Hojung C, Chang YL, Eun-Young P, Kyoung ML, Dongyun S, Hee-Sook J. Design, synthesis and effects of novel phenylpyrimidines as glucagon receptor antagonists. *Bioorg & Med Chem.* 2018;26:5701-10.
 18. Vibhu J, Kamlendra SB. Synthesis, pharmacological evaluation and molecular docking studies of pyrimidine dione based DPP-4 inhibitors as antidiabetic agents. *J Molecular Structure.* 2018;1158:96-105.
 19. Samir MA, Yasser MZ, Sahar AA, Shahenda M, Ahmed MS. Design, synthesis, molecular modeling and biological evaluation of novel thiouracil derivatives as potential antithyroid agents. *Molecules.* 2018;23:2913:1-14.
 20. Meeta S, Nadeem S, Vidushi S, Sharad W. 5,6-Dihydropyrimidine-1(2H)-carbothioamides: Synthesis, *in vitro* GABA-AT screening, anticonvulsant activity and molecular modelling study. *Bioorg Chem.* 2018;77:56-67.
 21. Yi-Xiang X, Huan W, Xiao-Kang L, Sheng-Nan D, Wen-Wen L, Qi G, et al. Discovery of novel propargylamine-modified 4-aminoalkyl imidazole substituted pyrimidinylthiourea derivatives as multifunctional agents for the treatment of Alzheimer's disease. *Eur J Med Chem.* 2018;143:33-47.
 22. Jain KS, Chitre TS, Miniyar PB, Kathiravan MK, Bendre VS, Veer VS, et al. Biological and medicinal significance of pyrimidines. *Current Science.* 2006;90(6):793-803.
 23. Ahmad FE, Ahmed HE, Rehab FA, Ayman RB. Design, synthesis, *in vivo* anti-inflammatory, analgesic activities and molecular docking of some novel pyrazolone derivatives. *Med Chem.* 2015;5(10):458-466.
 24. Priyanka TP, Poojali PW, Kirti TP, Santosh SU, Jamale DK, Vibhute SS, et al. Simple and efficient one-pot novel synthesis of pyrazolo[3,4-b][1,8]naphthyridine and pyrazolo[3,4-d]pyrimido[1,2-a]pyrimidine derivatives as anti-inflammatory agents. *Res Chem Intermed.* 2018;44:1119-30.
 25. Mallu L, Indira VA, Dhakshanamurthy T. One pot multi-component synthesis of functionalized Spiro pyridine and pyrido [2,3-d]pyrimidine scaffolds and their potent *in vitro* anti-inflammatory and anti-oxidant investigations. *Chem Biol Drug Des.* 2018;1-9.
 26. Rania BB, Amany AA, Khaled RAA. Synthesis, cyclooxygenase inhibition, anti-

- inflammatory evaluation and ulcerogenic liability of new 1-phenylpyrazolo[3,4- d]pyrimidine derivatives. *J Enzyme Inhib Med Chem.* 2016;31(S2):6-12.
27. Gina NT, Salwa MF, Hayam MA, Mounir AK, Rasha AN, Ibrahim ML. Design, synthesis and evaluation of some pyrazolo[3,4-d]pyrimidines as anti- inflammatory agents. *Bioorg Chem.* 2018;78:358-71.
 28. Thirumurugan K, Sivalingam L, Dharman GD, Sam DP, Ramalakshmi N, Arul AS. Design, synthesis and anti-inflammatory activity of pyrimidine scaffold benzamide derivatives as epidermal growth factor receptor tyrosine e kinase inhibitors. *J Molecular Structure.* 2018;1171:541-50.